Braftovi (Encorafenib) Patent Expiration, LOE Window & CMS Spending

Braftovi (Encorafenib) by Pfizer: FDA Orange Book core substance LOE 2030-08-27 (last listed 2033-08-05), 0 AB generics, $162.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN210496 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-08-27
Last Listed Patent or Exclusivity Date2033-08-05
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$162.6M
2024 Medicare Part D Spend$138.1M
2024 Medicaid Spend$24.5M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 25.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.